Skip to main content
Top
Published in: Annals of Hematology 7/2008

01-07-2008 | Original Article

Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients

Authors: Nirmala Devi Baskaran, Gin Gin Gan, Kamarulzaman Adeeba

Published in: Annals of Hematology | Issue 7/2008

Login to get access

Abstract

The purpose of this study was to determine if the Multinational Association for Supportive Care in Cancer (MASCC) risk-index score is able to predict the outcome of febrile neutropenia in patients with underlying hematological malignancy and to look at the other possible predictors of outcome. A retrospective study of 116 episodes of febrile neutropenia in patients who were admitted to the hematology ward of a local medical center in Malaysia between January 1st 2004 and January 31st 2005. Patient characteristics and the MASCC score were compared with outcome. The MASCC score predicted the outcome of febrile neutropenic episodes with a positive predictive value of 82.9%, a sensitivity of 93%, and specificity of 67%. Other predictors of a favorable outcome were those patients who had lymphomas versus leukemias, duration of neutropenia of less than 7 days, low burden of illness characterized by the absence of an infective focus and absence of lower respiratory tract infection, a serum albumin of >25 g/l, and the absence of gram-negative bacteremia on univariate analysis but only serum albumin level, low burden of illness, and presence of respiratory infection were significantly associated with unfavorable outcome after multivariate analysis. The MASCC score is a useful predictor of outcome in patients with febrile neutropenia with underlying hematological malignancies. This scoring system may be adapted for use in local settings to guide the clinical management of patients with this condition.
Literature
1.
go back to reference Bodey GP, Buckley M, Sathe YS et al (1996) Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64:328–339 Bodey GP, Buckley M, Sathe YS et al (1996) Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64:328–339
2.
go back to reference Cengiz O, Kucer B, Sürmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma. Med Sci Monit 12(6):CR240–CR247PubMed Cengiz O, Kucer B, Sürmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma. Med Sci Monit 12(6):CR240–CR247PubMed
3.
go back to reference Chen HP, Chen TL, Lai CJ, Fung CP, Wong WW, Yu KW, Liu CY (2005) Predictors of mortality in Acinetobacter baumanii bacteremia. J Microbial Immunol Infect 38:127–136 Chen HP, Chen TL, Lai CJ, Fung CP, Wong WW, Yu KW, Liu CY (2005) Predictors of mortality in Acinetobacter baumanii bacteremia. J Microbial Immunol Infect 38:127–136
4.
go back to reference Cherif H, Johansson E, Bjorkholm K, Kalin M (2006) Feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed Cherif H, Johansson E, Bjorkholm K, Kalin M (2006) Feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed
5.
go back to reference de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2007) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer Oct 25 (ahead of print) de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2007) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer Oct 25 (ahead of print)
6.
go back to reference Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamerellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infec Dis 32:1715–1725CrossRef Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamerellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infec Dis 32:1715–1725CrossRef
7.
go back to reference Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef
8.
go back to reference Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E (2007) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer Sep 25 (ahead of print) Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E (2007) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer Sep 25 (ahead of print)
9.
go back to reference Kern WV (2001) Risk assessment and risk based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis 14:415–222PubMed Kern WV (2001) Risk assessment and risk based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis 14:415–222PubMed
10.
go back to reference Klaassen RJ, Goodman TR, Pham B, Doyle JJ (2000) “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18:1012–1019PubMed Klaassen RJ, Goodman TR, Pham B, Doyle JJ (2000) “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18:1012–1019PubMed
11.
go back to reference Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
12.
go back to reference Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30:S51–S59PubMedCrossRef Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30:S51–S59PubMedCrossRef
13.
go back to reference Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, Yu KW, Wong WW, Liu CY (2004) Clinical characteristics and prognostic factors for patients with Stenotrophomonas maltophilia bacteremia. J Microbial Immunol Infect 37:350–358 Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, Yu KW, Wong WW, Liu CY (2004) Clinical characteristics and prognostic factors for patients with Stenotrophomonas maltophilia bacteremia. J Microbial Immunol Infect 37:350–358
14.
go back to reference McCabe WR, Jackson GG (1962) Gram negative bacteremia: etiology, clinical, laboratory, and therapeutic observations. Arch Intern Med 110:847–865 McCabe WR, Jackson GG (1962) Gram negative bacteremia: etiology, clinical, laboratory, and therapeutic observations. Arch Intern Med 110:847–865
15.
go back to reference Neth O, Hann I, Turner MW, Klein NJ (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358:614–618PubMedCrossRef Neth O, Hann I, Turner MW, Klein NJ (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358:614–618PubMedCrossRef
16.
go back to reference Ohyashki K (2004) Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients. Clin Infect Dis 39:56–58CrossRef Ohyashki K (2004) Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients. Clin Infect Dis 39:56–58CrossRef
17.
go back to reference Rubin M, Hathorn JW, Pizzo PA (1988) Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6:167–184PubMedCrossRef Rubin M, Hathorn JW, Pizzo PA (1988) Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6:167–184PubMedCrossRef
18.
go back to reference Santolaya ME, Alvarez AM, Becker A et al (2001) Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 19:3415–3421PubMed Santolaya ME, Alvarez AM, Becker A et al (2001) Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 19:3415–3421PubMed
19.
go back to reference Secmeer G, Devrim I, Kara A et al (2007) Role of procalcitonin and CRP in differentiating a stable from a clinical deteriorated course in pediatric febrile neutropenia. J Pediatr Hemat Oncol 29:107–111CrossRef Secmeer G, Devrim I, Kara A et al (2007) Role of procalcitonin and CRP in differentiating a stable from a clinical deteriorated course in pediatric febrile neutropenia. J Pediatr Hemat Oncol 29:107–111CrossRef
20.
go back to reference Alici S, Kaya S, Izmirli M et al (2006) Analysis of survival factors in patients with advanced stage gastric adenocarcinoma. Med Sci Monit 12(5):CR221–CR229PubMed Alici S, Kaya S, Izmirli M et al (2006) Analysis of survival factors in patients with advanced stage gastric adenocarcinoma. Med Sci Monit 12(5):CR221–CR229PubMed
21.
go back to reference Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Internal Med 148:2501–2568CrossRef Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Internal Med 148:2501–2568CrossRef
22.
go back to reference Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia; a prospective, two-centre validation of a prediction rule. J Clin Oncol 10:316–322PubMed Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia; a prospective, two-centre validation of a prediction rule. J Clin Oncol 10:316–322PubMed
23.
go back to reference Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association for Supportive Care in Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association for Supportive Care in Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef
24.
go back to reference Viscoli C (2002) EORTC International Antimicrobial Therapy Group. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 38:S82–S87PubMedCrossRef Viscoli C (2002) EORTC International Antimicrobial Therapy Group. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 38:S82–S87PubMedCrossRef
25.
go back to reference Viscoli C, Castagnola E (2002) Treatment of febrile neutropenia: what is new. Curr Opin Infect Dis 15:377–382PubMed Viscoli C, Castagnola E (2002) Treatment of febrile neutropenia: what is new. Curr Opin Infect Dis 15:377–382PubMed
26.
go back to reference Yadegarynia D, Tarrand J, Raad I, Rolston K (2003) Current spectrum of bacterial infections in patients with cancer. Clin Infec Dis 37:1144–1145CrossRef Yadegarynia D, Tarrand J, Raad I, Rolston K (2003) Current spectrum of bacterial infections in patients with cancer. Clin Infec Dis 37:1144–1145CrossRef
Metadata
Title
Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients
Authors
Nirmala Devi Baskaran
Gin Gin Gan
Kamarulzaman Adeeba
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0487-7

Other articles of this Issue 7/2008

Annals of Hematology 7/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.